PMID- 32791742
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Water vapor thermal therapy for lower urinary tract symptoms secondary to benign 
      prostatic hyperplasia: Systematic review and meta-analysis.
PG  - e21365
LID - 10.1097/MD.0000000000021365 [doi]
LID - e21365
AB  - BACKGROUND: Water vapor thermal therapy (WVTT) is a minimally invasive procedure 
      for treatment of lower urinary tract symptoms secondary to benign prostatic 
      hyperplasia (BPH). There are no known systematic reviews reporting the 
      effectiveness and safety of this increasingly common BPH therapy. METHODS: We 
      performed a systematic review and meta-analysis of studies utilizing WVTT for 
      symptomatic BPH. The international prostate symptom score (IPSS), IPSS-quality of 
      life (IPSS-QOL), BPH impact index (BPHII), and maximum flow rate (Qmax) were 
      calculated as the weighted mean difference relative to baseline and reported in 
      minimal clinically important difference (MCID) units. MCID thresholds were -3 for 
      IPSS, -0.5 for IPSS-QOL, -0.5 for BPHII, and 2 mL/s for Qmax. The surgical 
      retreatment rate was calculated using life-table methods. RESULTS: We identified 
      5 cohorts treated with WVTT from 4 studies (514 patients; 40% with median lobe 
      obstruction) with 2 years median follow-up (range: 6 months to 4 years). The 
      IPSS, IPSS-QOL, BPHII, and Qmax significantly improved at all intervals between 3 
      months and 4 years; this benefit ranged from 3.3 to 3.8 MCID units for IPSS, 3.9 
      to 4.6 MCID units for IPSS-QOL, 6.8 to 8.2 MCID units for BPHII, and 1.5 to 3.0 
      MCID units for Qmax. The surgical retreatment rate was 7.0% at 4 years of 
      follow-up data. Most adverse events were nonserious and transient; dysuria, 
      urinary retention, and urinary tract infection were most common. No cases of de 
      novo erectile dysfunction occurred. CONCLUSIONS: WVTT provided improvement in BPH 
      symptoms that exceeded established MCID thresholds, preserved sexual function, 
      and was associated with low surgical retreatment rates over 4 years.
FAU - Miller, Larry E
AU  - Miller LE
AUID- ORCID: 0000-0003-1594-1885
AD  - Miller Scientific, Johnson City, TN.
FAU - Chughtai, Bilal
AU  - Chughtai B
AD  - Department of Urology, Department of Obstetrics and Gynecology, Weill Cornell 
      Medicine, New York, NY.
FAU - McVary, Kevin
AU  - McVary K
AD  - Center for Male Health, Department of Urology, Stritch School of Medicine, Loyola 
      University Medical Center, Maywood, IL.
FAU - Gonzalez, Ricardo R
AU  - Gonzalez RR
AD  - Houston Methodist Hospital, Houston, TX.
FAU - Rojanasarot, Sirikan
AU  - Rojanasarot S
AD  - Boston Scientific, Marlborough, MA.
FAU - DeRouen, Kyle
AU  - DeRouen K
AD  - Boston Scientific, Marlborough, MA.
FAU - Bhattacharyya, Samir
AU  - Bhattacharyya S
AD  - Boston Scientific, Marlborough, MA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Steam)
SB  - IM
MH  - *Ablation Techniques
MH  - Humans
MH  - Lower Urinary Tract Symptoms/etiology/*therapy
MH  - Male
MH  - Prostatic Hyperplasia/*complications
MH  - Steam
PMC - PMC7387023
EDAT- 2020/08/15 06:00
MHDA- 2020/08/22 06:00
PMCR- 2020/07/24
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
PHST- 2020/07/24 00:00 [pmc-release]
AID - 00005792-202007240-00088 [pii]
AID - MD-D-20-01310 [pii]
AID - 10.1097/MD.0000000000021365 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21365. doi: 
      10.1097/MD.0000000000021365.